FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106020163> ?p ?o ?g. }

• W2106020163 endingPage "519" @default.
• W2106020163 startingPage "510" @default.
• W2106020163 abstract "BACKGROUND AND PURPOSE: Ultrasmall superparamagnetic iron oxide particles result in shortening of T1 and T2 relaxation time constants and can be used as MR contrast agents. We tested four hypotheses by evaluating MR images of intracranial tumors after infusion of two iron oxide agents in comparison with a gadolinium chelate: 1) Ferumoxtran in contrast to ferumoxides can be used as an intravenous MR contrast agent in intracranial tumors; 2) ferumoxtran enhancement, albeit delayed, is similar to gadolinium enhancement; 3) ferumoxtran-enhanced MR images in contrast to gadolinium-enhanced MR images may be compared with histologic specimens showing the cellular location of iron oxide particles; 4) ferumoxtran can serve as a model for viral vector delivery. METHODS: In 20 patients, ferumoxides and ferumoxtran were intravenously administered at recommended clinical doses. MR imaging was performed 30 minutes and 4 hours after ferumoxides infusion (n = 3), whereas ferumoxtran-enhanced MR imaging (n = 17) was performed 6 and 24 hours after infusion in the first five patients and 24 hours after infusion in the remaining 12. MR sequences were spin-echo (SE) T1-weighted, fast SE T2- and proton density–weighted, gradient-recalled-echo T2*-weighted, and, in four cases, echo-planar T2-weighted sequences. Representative regions of interest were chosen on pre- and postcontrast images to compare each sequence and signal intensity. RESULTS: Despite some degree of gadolinium enhancement in all tumors, no significant T1 or T2 signal intensity changes were seen after ferumoxides administration at either examination time. Fifteen of 17 patients given ferumoxtrans had T1 and/or T2 shortening consistent with iron penetration into tumor. Histologic examination revealed minimal iron staining of the tumor with strong staining at the periphery of the tumors. CONCLUSION: 1) Ferumoxtran can be used as an intravenous MR contrast agent in intracranial tumors, mostly malignant tumors. 2) Enhancement with ferumoxtran is comparable to but more variable than that with the gadolinium chelate. 3) Histologic examination showed a distribution of ferumoxtran particles similar to that on MR images, but at histology the cellular uptake was primarily by parenchymal cells at the tumor margin. 4) Ferumoxtran may be used as a model for viral vector delivery in malignant brain tumors." @default.
• W2106020163 created "2016-06-24" @default.
• W2106020163 creator A5002536570 @default.
• W2106020163 creator A5009470703 @default.
• W2106020163 creator A5014536479 @default.
• W2106020163 creator A5018310479 @default.
• W2106020163 creator A5048805399 @default.
• W2106020163 creator A5055576836 @default.
• W2106020163 creator A5055827273 @default.
• W2106020163 creator A5062539451 @default.
• W2106020163 creator A5086751696 @default.
• W2106020163 date "2002-04-01" @default.
• W2106020163 modified "2023-10-12" @default.
• W2106020163 title "Comparison of Two Superparamagnetic Viral-Sized Iron Oxide Particles Ferumoxides and Ferumoxtran-10 with a Gadolinium Chelate in Imaging Intracranial Tumors" @default.
• W2106020163 cites W14292534 @default.
• W2106020163 cites W1832752270 @default.
• W2106020163 cites W1965951866 @default.
• W2106020163 cites W1967434983 @default.
• W2106020163 cites W1974276386 @default.
• W2106020163 cites W1978042223 @default.
• W2106020163 cites W1992295328 @default.
• W2106020163 cites W1992469998 @default.
• W2106020163 cites W1997492046 @default.
• W2106020163 cites W2006793480 @default.
• W2106020163 cites W2011272082 @default.
• W2106020163 cites W2015607636 @default.
• W2106020163 cites W2022047142 @default.
• W2106020163 cites W2026791658 @default.
• W2106020163 cites W2028131143 @default.
• W2106020163 cites W2031054493 @default.
• W2106020163 cites W2046863310 @default.
• W2106020163 cites W2049995305 @default.
• W2106020163 cites W2052850794 @default.
• W2106020163 cites W2081854856 @default.
• W2106020163 cites W2086535395 @default.
• W2106020163 cites W2088667180 @default.
• W2106020163 cites W2090938843 @default.
• W2106020163 cites W2105249644 @default.
• W2106020163 cites W2106302531 @default.
• W2106020163 cites W2122854093 @default.
• W2106020163 cites W2136086537 @default.
• W2106020163 cites W2137837999 @default.
• W2106020163 cites W2150536544 @default.
• W2106020163 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7975083" @default.
• W2106020163 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11950637" @default.
• W2106020163 hasPublicationYear "2002" @default.
• W2106020163 type Work @default.
• W2106020163 sameAs 2106020163 @default.
• W2106020163 citedByCount "36" @default.
• W2106020163 countsByYear W21060201632013 @default.
• W2106020163 countsByYear W21060201632014 @default.
• W2106020163 countsByYear W21060201632015 @default.
• W2106020163 countsByYear W21060201632016 @default.
• W2106020163 countsByYear W21060201632017 @default.
• W2106020163 countsByYear W21060201632018 @default.
• W2106020163 countsByYear W21060201632019 @default.
• W2106020163 countsByYear W21060201632020 @default.
• W2106020163 countsByYear W21060201632022 @default.
• W2106020163 countsByYear W21060201632023 @default.
• W2106020163 crossrefType "journal-article" @default.
• W2106020163 hasAuthorship W2106020163A5002536570 @default.
• W2106020163 hasAuthorship W2106020163A5009470703 @default.
• W2106020163 hasAuthorship W2106020163A5014536479 @default.
• W2106020163 hasAuthorship W2106020163A5018310479 @default.
• W2106020163 hasAuthorship W2106020163A5048805399 @default.
• W2106020163 hasAuthorship W2106020163A5055576836 @default.
• W2106020163 hasAuthorship W2106020163A5055827273 @default.
• W2106020163 hasAuthorship W2106020163A5062539451 @default.
• W2106020163 hasAuthorship W2106020163A5086751696 @default.
• W2106020163 hasConcept C104293457 @default.
• W2106020163 hasConcept C126838900 @default.
• W2106020163 hasConcept C142724271 @default.
• W2106020163 hasConcept C143409427 @default.
• W2106020163 hasConcept C178790620 @default.
• W2106020163 hasConcept C185592680 @default.
• W2106020163 hasConcept C2989005 @default.
• W2106020163 hasConcept C557651011 @default.
• W2106020163 hasConcept C71924100 @default.
• W2106020163 hasConceptScore W2106020163C104293457 @default.
• W2106020163 hasConceptScore W2106020163C126838900 @default.
• W2106020163 hasConceptScore W2106020163C142724271 @default.
• W2106020163 hasConceptScore W2106020163C143409427 @default.
• W2106020163 hasConceptScore W2106020163C178790620 @default.
• W2106020163 hasConceptScore W2106020163C185592680 @default.
• W2106020163 hasConceptScore W2106020163C2989005 @default.
• W2106020163 hasConceptScore W2106020163C557651011 @default.
• W2106020163 hasConceptScore W2106020163C71924100 @default.
• W2106020163 hasIssue "4" @default.
• W2106020163 hasOpenAccess W2106020163 @default.
• W2106020163 hasRelatedWork W1972344593 @default.
• W2106020163 hasRelatedWork W1972582749 @default.
• W2106020163 hasRelatedWork W1984232298 @default.
• W2106020163 hasRelatedWork W1992034168 @default.
• W2106020163 hasRelatedWork W1992848513 @default.
• W2106020163 hasRelatedWork W1994139105 @default.
• W2106020163 hasRelatedWork W2004048765 @default.
• W2106020163 hasRelatedWork W2006858976 @default.
• W2106020163 hasRelatedWork W2011272082 @default.

• next